A fundamental flaw driving the very low success in drug R&D is that existing disease models do not reliably represent human biology.  We have developed a transformational platform, REVEAL-Tx™, which applies principles of physiological blood flow to tissue from patients to recapitulate human disease and allow drug candidates to be studied at human relevant concentrations.  REVEAL-Tx™ provides us with unprecedented insights into complex pathophysiological pathways by replicating human disease with great accuracy. 

To date, our platform has been used to recreate nearly twenty human disease states related to liver, vascular and tumor biology, including those driving our current pipeline in propionic acidemia, methylmalonic acidemia and nonalcoholic steatohepatitis (NASH).  Our human disease models, in combination with our advanced proprietary computational biology tools, reduce risk of failure by enabling us to deeply interrogate disease pathways, test hypotheses and select meaningful drug targets under physiologically accurate disease conditions.